|
Patent landscape, scope, and claims: |
US Patent 7,112,592 Landscape: What Is Covered, Claim Scope, and Where Generics or Licensing Can Hit
US Patent 7,112,592 is a chemistry-led patent family centered on broad Markush-structured trans-7-oxo-1,6-diazabicyclo[3,2,1]octane-type scaffolds with highly variable substituents (notably aromatic/heteroaromatic R groups and “B” sidechain variants), plus coverage for salts, pharmaceutical compositions, and a method of treating bacterial infections via bactericidally effective dosing. The claim set is both wide (large substituent ranges) and anchored by a specific core bicyclic lactam/amide framework, with several dependent claims and an explicit enumerated “selected compounds” block.
What patents protect the trans-7-oxo-1,6-diazabicyclo[3,2,1]octane compound class in US 7,112,592?
Direct protection in US 7,112,592 is for:
- Compounds defined by a complex Markush formula (independent claim 1, plus related independents including 9 and 15).
- Specific enumerated embodiments (claim 8 lists multiple concrete structures and salts).
- Pharmaceutical compositions (claims 18–21).
- Method of treatment: bacterial infections in warm-blooded animals (claim 22).
Key functional/legal takeaway: The estate is not just “a molecule.” It covers a scaffold with substituent latitude, which can matter for freedom-to-operate (FTO) around analogs, prodrugs/salts, and formulation-based licensing.
What are the core claim anchors (independent claim 1)?
Independent claim 1 defines, in aggregate:
- A bicyclic diazabicyclo[3,2,1]octane-type core with a trans-7-oxo-type relationship.
- A substitution system governed by variables R1, R2, R3, R4, A, X, n, n′, n″, B, plus substituent families for R, R5, R6, R7, R8 and phosphate/sulfate/sulfonamide/tetrazole-like options via Y, Y1, Y2, Y3.
- Salts with base or acid are expressly included.
- A structural constraint: when n=1 and A is in certain states, R1, R2, R3 cannot all be hydrogen simultaneously.
How do independent claims 9 and 15 differ from claim 1?
- Claim 9 is another independent Markush formula claim with similar variable sets but different definitional constraints for the “B” and “n″” degrees of freedom (notably n″ is 0 or 1 in claim 9 and B is defined accordingly).
- Claim 15 is narrower in one critical way: R1 is specifically —CONR6R7, B is fixed as —NR8—(CH2)n″ attached to the carbonyl, with n″ = 0. It also keeps the same “Y/Y1/Y2/Y3” functional substitution universe for R8.
Net effect: Claim 15 reads like a “focus” dependent on the same scaffold but with tightened carbonyl substitution and reduced variability in the B linkage.
What is the explicit “selected compounds” protection in claim 8?
Claim 8 directly enumerates named embodiments (and their salts). It includes, verbatim in concept:
- trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide
- analogs with N-substitution including:
- N-(phenylmethyl)
- N-(4-pyridinyl methyl)
- N-(3-pyridinyl methyl)
- N-(2-amino 2-oxo ethyl)
- phenylmethyl trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxylate
Net effect: Even if an accused product is outside the broad Markush perimeter, claim 8 can still pin down specific members of the series and salts.
What downstream protection exists in the same patent?
- Pharmaceutical compositions: claims 18–21 each cover formulations where the active is a compound of claims 1, 8, 9, or 15 plus a “pharmaceutical acceptable carrier.”
- Method of treatment: claim 22 covers administration of a bactericidally effective amount to warm-blooded animals for bacterial infections.
How broad are the chemical variables and what does that mean for infringement risk?
US 7,112,592 uses a classic “large Markush with nested functional group definitions” structure. The practical scope is best analyzed by breaking the variables into (1) scaffold, (2) N-substitution (B/R8), (3) aromatic/alkyl R groups, and (4) ionizable/solubilizing handles (Y/Y1/Y2/Y3).
1) Scaffold + oxo/carbonyl placement
Across claims 1/9/15, the bicyclic core is preserved and “oxo/carboxamide/carboxylate”-like functions are integral. That means infringement arguments will typically focus on whether a competitor retains the same bicyclic framework and the relative carbonyl/heteroatom placements.
2) R groups on carbon carriers and N-linked substituents
- R1 spans hydrogen, COOH, CN, ester/amide forms, and “(CH2)n′R5” plus a broad substituent set for R (alkyl 1–6C, alk(en)yl 3–9C, aryl 6–10C, aralkyl 7–11C, with aryl substitution by OH/NH2/NO2/alkyl/alkoxy/halogen).
- R6/R7 span H, alkyl 1–6C, aryl 6–10C, aralkyl 7–11C, and substituted carbamoyl/ureido/dimethylamino-like motifs.
This breadth increases infringement exposure to “substitution variants” that maintain the same core and bonding topology, particularly where R5 is an acyl/heterocycle precursor (COOH/CN/CH2 tetrazole/sulfonamide-like functions).
3) B-sidechain linkage and its degree of freedom (n″)
- Claim 1 includes detailed options for X as —C(O)—B— attached to the nitrogen by the carbon and defines B such as —O—(CH2)n″ or —NR8—(CH2)n″ or —NR8—O— attached to the carbonyl by the nitrogen, with n″ = 0 in claim 1.
- Claim 9 relaxes n″ to 0 or 1.
- Claim 15 fixes n″ = 0.
Practical risk: If an alternative synthesis route yields a different linker length or oxygen vs nitrogen connectivity in the “B” portion, it can become a non-infringement lever, depending on which independent claim is asserted.
4) Solubilizing/ionizable “Y” families
The Y variables include:
- carboxylic acid and acyl functions (—COH, —COR, —COOR),
- amides and substituted amides (—CONH2/—CONHR),
- nitrile-like (—CH2CONHCN),
- heterocycles such as (protected) CH2 tetrazole,
- sulfonic/sulfone-like (—CH2SO3H, —CH2SO2R),
- phosphates (—CH2PO(OR)2, —CH2PO(OH)(OR), etc.),
- and variants “Y1/Y2/Y3” for narrower subfamilies.
This means the estate is positioned to cover common prodrug/solubility-tail strategies if they retain the same scaffold and the corresponding definition for Y/Y1/Y2/Y3.
What patents protect formulations and methods, and how do claims 18–22 extend coverage?
Pharmaceutical composition claims (18–21)
Each composition claim is a standard “active + pharmaceutically acceptable carrier” construct. Under US practice, these generally offer:
- Direct infringement for marketing and dispensing of a covered active in a covered formulation, even where the exact compound might be argued under composition-level proof.
- A pathway for asserting claims even if a product is a salt form, provided the salt maps to included “compound” coverage.
Method-of-use claim (22)
Claim 22 covers:
- Warm-blooded animals
- administration of a bactericidally effective amount
- for bacterial infections
Practical infringement posture: Method claims can be harder to enforce absent prescription/labeling evidence that a covered compound is used for that purpose at a bactericidal effective dose. But if the marketed product’s label or practice aligns with “bacterial infections” and the active ingredient is within claims 1/8/9/15, claim 22 can be leveraged.
Where does US 7,112,592 sit in the broader patent landscape?
A full “family landscape” requires bibliographic and citation data (continuations, priority chain, related US filings, corresponding WO publications, and who owns/assignees). The prompt provides only the claim text, not:
- patent publication numbers,
- assignee/owner,
- filing/priority dates,
- prosecution history,
- family members (continuations/divisionals),
- or the patent’s position in an Orange Book or competitor litigation set.
Given the constraint to produce complete and accurate landscape analysis only from provided information, no additional family-member or litigation/Orange Book mapping can be stated here.
What does the scope imply for generic or biosimilar entry risks?
This is a small-molecule antibiotic scaffold patent, so “biosimilar” concepts are not the primary risk vector. The risk vector is:
- structural design-around (changing the scaffold or prohibited variable combinations, especially B-linkage and carbonyl/connectivity),
- salt/prodrug selection (ensuring the Y/Y1/Y2/Y3 definitions do not map),
- formulation (but composition claims 18–21 make simple “active + carrier” formulations risky if the active is inside the compound claims),
- labeling/indication (method claim 22 is strongest where the marketed use is explicitly for bacterial infections at bactericidal dosing).
Key independent-claim coverage map (quick reference)
| Claim |
Coverage type |
Scope narrowing features present in claim text |
| 1 |
Broad Markush compound claim |
Includes wide R1/R2/R3/R4/A/X/B variable space; includes salts; has a “R1/R2/R3 cannot all be hydrogen” constraint under specific conditions |
| 8 |
Explicit enumerated compound list + salts |
Lists multiple concrete trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide/caboxylate embodiments including pyridylmethyl and amino-oxo-ethyl derivatives |
| 9 |
Independent Markush compound claim |
Similar scaffold but with defined variable restrictions (notably n″ = 0 or 1 for B definition) |
| 15 |
Narrower independent Markush |
Forces R1 = —CONR6R7 and fixes B as —NR8—(CH2)n″ with n″ = 0 |
| 18–21 |
Pharmaceutical compositions |
“Active ingredient = compound of claim 1/8/9/15 + pharmaceutically acceptable carrier” |
| 22 |
Method of treatment |
Administration of bactericidally effective amount to warm-blooded animals for bacterial infections |
Key Takeaways
- US 7,112,592 protects a trans-7-oxo bicyclic diazabicyclo scaffold with large substituent latitude, including salts, specific enumerated sulphooxy carboxamide/caboxylate embodiments, pharmaceutical compositions, and a bacterial-infection method-of-use claim.
- Independent claims 1, 9, and 15 cover overlapping but not identical Markush territories. Claim 15 is the most structurally constrained independent.
- The most litigation-relevant structural differentiators embedded in the text are the B/X linkage topology and n″, the carbonyl/substituent constraints (notably R1 = —CONR6R7 in claim 15), and the R-group families plus Y/Y1/Y2/Y3 solubilizing handles.
- Composition claims (18–21) and method claim (22) extend enforcement beyond the exact compound if the active ingredient falls within the compound claims.
FAQs
- What does “dotted line representing an optional bond” mean for infringement under US 7,112,592?
- Which variables in claim 1 are most important for a design-around (R1 vs B-linker vs Y/Y1/Y2/Y3)?
- Do salts of the enumerated sulphooxy carboxamide embodiments (claim 8) receive separate coverage?
- How does claim 15’s fixed n″ = 0 constraint narrow the B-linker options compared with claim 9?
- Can the method claim 22 apply to veterinary uses outside “warm-blooded animals” labeling?
References
- US Patent 7,112,592 (claims text provided in prompt).
More… ↓
⤷ Start Trial
|
